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Purpose: Patients with biliary atresia (BA) treated with Kasai portoenterostomy may later develop intractable cholangitis 
(IC) that is unresponsive to routine conservative treatment. It may cause biliary cirrhosis and eventually hepatic failure with 
portal hypertension. Control of IC requires prolonged hospitalization for the administration of intravenous antibiotics. To re-
duce the hospitalization period, we designed a home intravenous antibiotic treatment (HIVA) which can be administered af-
ter initial inpatient treatment. In this study, we reviewed the effects of this treatment. Methods: We reviewed medical records 
of 10 patients treated with HIVA for IC after successful Kasai portoenterostomies performed for BA between July 1997 and 
June 2009. Results: The duration of HIVA ranged from 8 to 39 months (median, 13.5 months). The median length of hospital 
stay was 5.7 days per month for conventional treatments to manage IC before HIVA and, 1.5 days per month (P = 0.012) after 
HIVA. The median amount of medical expenses per month was reduced by about one tenth with HIVA. One patient under-
went liver transplantation due to uncontrolled esophageal variceal bleeding, but the other nine patients had acceptable hep-
atic function with native livers. Conclusion: HIVA may be an effective primary treatment for IC after Kasai portoenteros-
tomies for BA, and reduce length of hospital stay and medical expense.
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INTRODUCTION
After several years of managing cholangitis in biliary 
atresia (BA), we recognized that a small group of patients 
required prolonged intravenous (IV) antibiotic treatment 
to prevent recurrent cholangitis. In this group, oral anti-
biotic treatment was not effective enough to prevent chol-
angitis, and the discontinuation of IV antibiotic treatment 
led to recurrent cholangitis attacks. Thus, these patients 
had intractable cholangitis (IC) that could not be con-
trolled by routine conservative treatment. In addition, the 
IC was usually associated with intrahepatic biliary cysts 
(IHBCs) and required hospitalization for several months 
or several years. The long period of hospitalization occa-
sionally resulted in the breakup of the patient’s family, 
which would be “the worst disaster for the patients.” For 
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the management of IC, we developed a home intravenous 
antibiotic treatment (HIVA) based on the idea of home to-
tal parenteral nutrition (TPN) for short bowel syndrome.
To evaluate the role of HIVA in patients with IC follow-
ing Kasai portoenterostomies, we reviewed records of 10 
patients who had been treated at our institution.
METHODS 
We retrospectively reviewed medical records of pa-
tients who had been treated with HIVA for IC after suc-
cessful Kasai portoenterostomies performed for BA be-
tween July 1997 and June 2009. Successful Kasai portoen-
terostomy was defined as when the serum total bilirubin 
decreased to the level less than 2 mg/dL within 6 months of 
Kasai procedure. Cholangitis was diagnosed in patients 
who had underwent the Kasai procedure and then devel-
oped fever without another identifiable source of infection 
plus the following criteria: 1) clinical symptoms such as re-
appearance of jaundice or acholic stool; and 2) laboratory 
evidence of sudden elevation of serum bilirubin or liver 
enzymes (alanine transaminase [ALT] or aspartate trans-
aminase [AST]); or 3) isolation of bacteria on blood 
culture. IC was defined as recurrent cholangitis for 1) hos-
pitalization for the treatment of cholangitis for longer than 
1 month and 2) three consecutive hospitalizations due to 
cholangitis with an interval less than 1 month between the 
previous discharge and re-admission. Abdominal ultra-
sonography, computed tomography or magnetic reso-
nance cholangiopancreatography was performed to de-
tect IHBCs in all patients diagnosed as IC.
When fever subsided and cholangitis was controlled 
with optimal intravenous antibiotics treatment during 
hospitalization, a Broviac catheter (Bard Access Systems 
Inc., Salt Lake City, UT, USA) was placed in the central vein 
of the patients before they were discharged from the 
hospital. The catheter was inserted under general anes-
thesia, and remained for the full course of HIVA. After dis-
charge, home care nurse or the patients’ parent(s) or 
guardians administered intravenous antibiotic treatment 
via the catheter in the same way it was done during 
hospitalization. To prevent re-hospitalization due to the 
recurrent cholangitis a few days later after discharge, they 
were managed with HIVA after discharge. They were 
checked up every month at out-patient clinic.
During monthly follow-up at out-patient clinic, the 
completion time for HIVA was determined. Within 6 to 8 
months after HIVA, the discontinuation of HIVA or the 
switch from HIVA to oral antibiotic treatment was tried 
without removal of intravenous access. If cholangitis re-
curred without intravenous antibiotics treatment, HIVA 
was restarted using the intravenous catheter. If cholangitis 
did not recur without HIVA for a few months, intravenous 
catheter was removed and HIVA was completed.
If cholangitis attacks took place during the course of 
HIVA, patients were re-admitted and blood culture test 
was performed. Intravenous antibiotics were changed to 
the other kinds according to the sensitivity test result of 
blood culture if the resistant strain to the previous anti-
biotics was found in the blood culture study.
Admission rates (admission days per month of the con-
servative treatment period) and hospital expenses before 
HIVA (from the time of diagnosis of IC to the time HIVA 
started) were compared to those after HIVA (including the 
cost for HIVA such as drugs and home are nursing, and the 
cost for follow-up in out-patient clinic during and after 
discontinuance of HIVA) for each patient by the Wilcoxon 
signed rank test using the SPSS ver. 13.0 (SPSS Inc., 
Chicago, IL, USA). The study was approved by our institu-
tional review board (approval number: 4-2009-0529). 
Anonymity and privacy of the patients were protected.
RESULTS
One hundred six patients underwent Kasai portoenter-
ostomies at our hospital between July 1997 and June 2009. 
Among them, 90 patients had follow-up records over the 
last 3 years.
Kasai portoenterostomies were unsuccessful in nine 
patients. The levels of serum bilirubin never dropped to 
less than 2 mg/dL after these nine Kasai procedures. Three 
patients among these nine patients presented with IC. 
Eighty-one patients were followed-up after successful 
Kasai procedures. Another patient was referred to our in-
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Fig. 1. The occurrence of intrac-
table cholangitis (IC) and the 
application of home intravenous 
antibiotic treatment (HIVA) after 
Kasai portoenterostomies bet-
ween July 1997 and June 2009. 
Case Sex
Age at 
Kasai op. 
(day)
Age at 
IC (mo)a)
Interval b/w 
IC-HIVA 
(mo)b)
Duration 
of HIVA 
(mo)
 1 F 70    6 54  1
2 M 86    5 28 16
3 M 23    6   2 8
4 M 43    8   2 18
5 F 63    8   2 8
  6c) F 40    5   4 39
7 F 56 12   0 9
8 F 46   4   1 12
9 F 56 12   1 15 (on Tx.)
10 F 77 35   1  8 (on Tx.)
Median - 56   7   2 13.5
op, operation; IC, intractable cholangitis; Tx, treatment.
a)Age at diagnosis of IC; b)Time from the diagnosis of IC to the start 
of HIVA; c)Case underwent Kasai procedure at another hospital.
Table 1. Clinical characteristics of 10 patients treated by the home 
intravenous antibiotic treatment (HIVA) program
stitution for IC management after undergoing a successful 
Kasai procedure at another hospital. Among these 82 pa-
tients whose postoperative levels of serum bilirubin were 
normalized (less than 2 mg/dL) within 6 months after 
Kasai portoenterostomies, 13 patients (15.9%) suffered 
from IC. Only 10 of them received HIVA. HIVA could not 
be applied for the other three patients because IC was not 
controlled by intravenous antibiotics treatment during 
hospitalization. Two of them underwent liver trans-
plantation because of IC, and one died of sepsis and vari-
ceal bleeding following IC (Fig. 1).
Table 1 summarizes the clinical characteristics of the 10 
patients enrolled in HIVA program. They underwent 
Kasai portoenterostomies from 23 to 86 days (median, 56 
days) of age. The median age at diagnosis of IC was 7 
months (range, 4 to 35 months).
Fig. 2 outlines the progression and resolution of IC in 
some of the patients. Before conceiving the idea of HIVA, 
we struggled to control recurrent cholangitis by surgical 
or interventional modalities, such as hepatic cystojeju-
nostomy, revision of portoenterostomy, percutaneous 
transhepatic biliary drainage, alcohol sclerosing treat-
ment, or metal stent insertion in the initial two patients 
(patients 1 and 2). In spite of those many attempts, cholan-
gitis attacked recurrently in those two patients. A few days 
after they were discharged from long hospitalization, they 
suffered from recurrent cholangitis and were re-admitted. 
Fig. 3 shows the IHBCs detected after the diagnosis of IC 
(Fig. 3A) and remained after hepatic cystojejunostomy 
(Fig. 3B) in patient 1. The time interval between the 
diagnosis of IC and the start of HIVA in patients 1 and 2 
was longer than in other patients (54 months for patient 1 
and 28 months for patient 2), because we attempted to 
treat IC with conventional procedures before using HIVA 
in these two patients. The unsuccessful outcomes of the 
interventions for these first two patients led us to develop 
HIVA. For patients 3 to 10, HIVA was applied as soon as IC 
was diagnosed. The median interval between the diagnosis 
of IC and the application of HIVA  was 2 months. The 
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Fig. 2. Progression and resolution of intractable cholangitis (IC) with home intravenous antibiotic treatment (HIVA): cholangitis events 
recurred in spite of several attempts to control IC before HIVA in the first 2 patients (patients 1 and 2). IC was eventually controlled by HIVA 
in all patients. PTBD, percutaneous transhepatic biliary drainage; Tx, treatment.
Fig. 3. (A) Intrahepatic biliary cysts (IHBCs) related to intractable cholangitis in patient 1 shown by magnetic resonance cholan-
giopancreatography. (B) Remaining IHBCs after hepatic cystojejunostomy in patient 1 shown by computed tomography.
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Case
Admission ratea)
Before HIVA After HIVA 
 1 4.4 2.0
2 9.9 1.1
5 9.1 2.0
6 5.2 0.0
7 6.2 0.0
8 5.2 0.0
9 7.0 4.7
10 4.7 3.3
Median   5.7b)  1.5b)
a)Hospital stay in days/months during conventional treatments 
(before HIVA) or HIVA. b)P = 0.012.
Table 3. Effect of home intravenous antibiotic treatment (HIVA) on
admission rate due to cholangitis
Case
Duration of 
follow-up after 
HIVA (mo)
IC on last 
follow-up
IHBC on last 
follow-up
T.Bil on last 
follow-up 
(mg/dL)
1 69 No Yesa) 1.1
2 66 No Yesa) 0.8
3 31    NCb) NC  0.6c)
4 76 No NC 0.4
5 68 No No 0.4
6 27 No No 1.1
7 50 No No 2.0
8 40 No No 0.5
9 -d) No No 1.5
10 -d) No Yes 1.1
Median 58   0.95
IC, intractable cholangitis; IHBC, intrahepatic biliary cyst; T.Bil, 
serum total bilirubin; NC, not checkable due to liver trans-
plantation.
a)Recurred with cholangitis after disappearance of IHBC with 
HIVA, but the size of IHBC was reduced compare with initial 
huge one by imaging studies (abdominal US, CT, or MRCP). 
b)Case of liver transplantation due to esophageal variceal bleeding 
at 31 months after HIVA. c)Before liver transplantation; d)On HIVA 
treatment.
Table 2. Results of home intravenous antibiotic treatment (HIVA)
duration of HIVA was determined by the tolerance of 
discontinuance of intravenous antibiotics treatment 
without recurrent cholangitis in each patient. It ranged 
from 8 to 39 months (median, 13.5 months) (Table 1).
Cholangitis recurred a few times after completion of 
HIVA in patients 1, 2, and 5 (Fig. 2). However, it was easily 
controlled with routine conservative management in 
hospitalization. All patients, except one (patient 3) who 
underwent liver transplantation due to variceal bleeding, 
are free of IC with native liver on last follow-up (median 
duration of follow-up: 58 months after HIVA) as shown in 
Table 2. All patients with native liver showed acceptable 
hepatic function and were jaundice-free. Their serum lev-
els of total bilirubin on last follow-up are listed in Table 2.
IHBCs disappeared on the follow-up abdominal ultra-
sonography within 2 years after the completion of HIVA in 
all patients who were followed up. Recurrent IHBCs asso-
ciated with cholangitis were detected on long-term (more 
than 2 years) follow-up in only the first two patients for 
whom application of HIVA was delayed (Table 2). IHBC 
was not detected in the other five patients (patients 5 to 9) 
for median duration for follow-up of 40 months (range, 15 
to 68 months).
The catheter related complication was occurred in two 
patients. One patient had catheter infection and the other 
had catheter occlusion. The complicated catheter was re-
moved and new catheter was reinserted. No patients de-
veloped antibiotics related complication.
The median hospital stay with conventional treatment 
before HIVA was 5.7 days per month and, after HIVA, 1.5 
days per month for eight patients for whom this data was 
recorded. This decrease in the admission rate after the 
completion of HIVA was significant (P = 0.012) (Table 3). 
The median amount of medical expenses for IC was about 
KRW 3.22 million per month before HIVA. It was reduced 
by about one tenth to KRW 392,806 per month after the ini-
tiation of HIVA. These results show that the median value 
of monthly medical expenses significantly decreased 
when HIVA was applied (P = 0.012).
DISCUSSION
Cholangitis is a common complication that develops af-
ter Kasai procedures for BA [1]. The reported incidence of 
postoperative cholangitis in BA ranges from 40 to 93% [2]. 
IC that cannot be controlled by routine conservative treat-
ment may lead to biliary cirrhosis and hepatic failure with 
portal hypertension. IC is considered as one of the most 
important and difficult complications to manage after 
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Kasai portoenterostomy because of the poor prognosis 
and the occasional requirement of liver transplantation. 
Recurrent cholangitis is one of the most important deter-
minants of prognosis after a successful Kasai procedure. 
The number of cholangitis episodes negatively affects 
long-term postoperative survival. IHBCs favor bacterial 
persistence and cause recurrent cholangitis [3]. The re-
ported incidence of IHBCs after hepatic portoenterostomy 
in biliary atresia ranges from 6.4 to 25.3% [4-7]. Major com-
plications that induce mortality from recurrent cholangitis 
include massive variceal bleeding and hepatic failure [8]. 
For these conditions, aggressive treatment and preventive 
modalities are needed.
In our patients with IC, cholangitis was not controlled 
by routine conservative management including intra-
venous antibiotics treatment during hospitalization. In 
less than one month, cholangitis recurred and the patient 
must be re-admitted. Frequent recurrence of cholangitis 
made the patients’ hepatic function poorer. The patients 
and their parents’ quality of life also became poorer after 
prolonged and repeated hospitalization for cholangitis 
treatment.
Many surgical and medical treatments have been sug-
gested for cholangitis and IHBCs, including systemic anti-
biotic therapy [4,7], percutaneous transhepatic cholangio-
drainage (PTCD) [4,5,7,9], alcohol injections [4], revision 
of portoenterostomy [4,10], laparotomy with internal in-
testinal drainage of an IHBC [5], Roux-en-Y reconstruction 
by limb lengthening and antireflux valve creation for me-
chanical problems related to bile drainage in Roux-en-Y 
limb [11], and liver resection for the localized IHBC [12]. 
These treatment modalities are limited in their ability to 
manage refractory cholangitis or IHBCs. PTCD is not ef-
fective in cases of noncommunicating cysts, and is difficult 
if the cysts are located in the porta hepatis because of the 
risk of jejunal or portal injury [4]. Bu et al. [7] reported that 
IHBCs disappeared with PTCD in only one of 39 patients 
with multiple IHBCs. Surgical intervention is also difficult 
to perform if cysts are located in the deep portion of the liv-
er [4]. In the first two patients (patients 1 and 2) of 10 pa-
tients who received HIVA, huge IHBC was drained by 
PTCD to resolve the IC because the IHBCs detected on 
imaging study were considered to be the infectious source 
of IC (Fig. 3A). However, cholangitis was not controlled by 
PTCD. We struggled to control IC with other interven-
tions. To control IC in these initial two patients, we per-
formed alcohol injections via the PTCD catheter, hepatic 
cystojejunostomy, internal metal stent insertion, or re-
vision of portoenterostomy, but cholangitis still did not re-
solve (Fig. 2, 3B). Failures of the above interventions led us 
to conceive of the HIVA program. Patients can be treated 
with IV antibiotics effective against cholangitis during a 
brief initial hospitalization and then discharged with 
HIVA. They can continue the treatment at home for a few 
months, controlling cholangitis.
During the HIVA follow-up period, cholangitis attacks 
became controllable in short hospitalization. The fre-
quency of cholangitis attack was reduced after HIVA 
application. In some patients, there was no cholangitis 
event at all after HIVA. Their hepatic function did not dete-
riorate during long-term follow-up, and they are good 
enough with their native liver. HIVA may be an effective 
primary treatment for IC after successful Kasai proce-
dures for BA. IHBCs related to IC can also be controlled 
and resolved with HIVA. IHBCs disappeared on the fol-
low-up imaging studies once recurrent cholangitis was 
controlled. IHBC recurred with cholangitis in patients 1 
and 2. However, cholangitis was controllable with routine 
treatment, and the size of IHBC was smaller than when it 
was accompanied with IC. According to the recurrence of 
IHBC in these 2 patients, the duration of suffering IC be-
fore HIVA and the duration before receiving Kasai por-
toenterostomy may have some important meaning. 
Considering cirrhotic change from bile congestion, longer 
the duration of IC or BA not controlled, more the biliary 
cirrhosis can be aggravated.
Three patients who suffered from IC after successful 
Kasai portoenterostomies did not respond to continuous 
IV antibiotics treatment while being hospitalized. In these 
patients, HIVA could not be applied (Fig. 1). One of them 
died from uncontrolled cholangitis and subsequent sepsis 
and variceal bleeding. In such a case, liver transplantation 
should be considered. The other two patients underwent 
liver transplantation, and the graft functioned well with-
out recurrent cholangitis after transplantation. If IC ini-
tially respond to IV antibiotics, HIVA can be applied to re-
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duce the likelihood of high morbidity from liver trans-
plantation. Before considering liver transplantation for IC, 
HIVA can be applied with effective IV antibiotics. Liver 
transplantation should be considered if they present hep-
atic failure or other complications from biliary cirrhosis or 
portal hypertension even after or during the IC treatment 
with HIVA as was the case for patient 3.
This would reduce the morbidity and mortality asso-
ciated with recurrent cholangitis in this population. The 
length of hospital stay and medical expenses associated 
with the control of IC can be significantly reduced by 
HIVA. Moreover, the hospital stay can be shortened or at 
least broken-up can be avoided by reducing stress placed 
on the family.
To improve the prognosis of IC or IHBCs, every effort 
should be made to diagnose IC as early as possible. If a pa-
tient with biliary atresia is found to have IC, HIVA should 
be applied without delay, as this may help maintain hep-
atic function, and reduce the risk of biliary cirrhosis and 
reduce length of hospital stay and medical expense.
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